About: Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 15 August 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2018 (uk) article scientifique publié en 2018 (fr) im August 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 2018 (ast) scientific article published on 15 August 2018 (en)
publication date	wds:Q57169180-9609036E-2C83-408C-A79A-8971A2FA7D13
publication date	2018-08-15 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57169180-406DC97B-1991-4A47-B11D-9B655D3F0330
language of work or name	English
cites work	wds:Q57169180-16BAD70F-845F-47B2-93E4-C4FF5901A4BD wds:Q57169180-2DC97284-8982-4AB5-927D-DF16D3436BC3 wds:Q57169180-381EF4B4-5F97-4FB7-87D8-5874DE7DE7B5 wds:Q57169180-3DF3BBE3-7783-47B3-AE29-88AE177123AF wds:Q57169180-478087CA-CF8F-4B68-B622-48E580B641A0 wds:Q57169180-5634A1FD-4357-4C08-B117-3FA517E4554E wds:Q57169180-5F8251B7-7513-427C-8F23-42A771709257 wds:Q57169180-665A522D-60C2-4474-9B46-C6481B0AFAAC wds:Q57169180-67432A08-3AC1-4D66-9A06-5D402E686A2B wds:Q57169180-67F318E3-E740-49D3-B88D-6B7B7211D665 wds:Q57169180-9C5DFF55-A714-4F65-86BE-90D5BD2C3F26 wds:Q57169180-AADDF29A-4D67-4312-8075-074E4075967B wds:Q57169180-B510E210-34C1-468E-9067-5469FBDE5F1E wds:Q57169180-C8D0B414-DA4B-4EC4-BB9D-DBAA649A1BCD wds:Q57169180-DA1ADA0B-74D7-4781-8160-C600C4A26749 wds:Q57169180-EAFE719B-CDEF-4108-B3D1-A59550AA8CA7
cites work	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
author name string	wds:Q57169180-07CE0777-13F1-4A2C-AD1A-9BD482D861A2 wds:Q57169180-12E2A0BB-39D4-49BA-92C5-687F41087ABA wds:Q57169180-3EDE1F79-9FB0-4697-918B-5A63A05B1F8A wds:Q57169180-424D1177-8C73-493D-AD02-D4B903CF4A6B wds:Q57169180-9E59EE23-5F4D-4ABA-B719-24C504459EC6 wds:Q57169180-ED136E97-CA1A-4322-989F-1818AB2D7C61
author name string	Ying Huang Nyla A Heerema Margaret Lucas Corinne Hoffman Mark A Reid W Thomas Whitlow
rdfs:label	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (en) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (nl)
skos:prefLabel	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (en) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (nl)
name	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (en) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (nl)
author	wds:Q57169180-0A1DB47F-38BC-4B6B-9F16-C37313738D5A wds:Q57169180-15FE077F-0FCE-4E1F-A4B6-2B89F2C4E694 wds:Q57169180-237C0E44-10C4-4EA1-86CB-755426FD0813 wds:Q57169180-411E0924-6EED-4FAB-8206-DF057659F7D7 wds:Q57169180-5371F359-920C-4D67-B2AE-A8C9CDAB1BD6 wds:Q57169180-61CF8B16-25E2-4F67-8B33-5D9EBDABC605 wds:Q57169180-930CDD93-EDC7-4712-AFF4-EF0C6E6E2956 wds:Q57169180-B998A732-3FC1-4A75-840D-DBE5802C8E87 wds:Q57169180-D82A432F-2111-449A-AA4E-5DA5CFED0DF9 wds:Q57169180-F8A51252-75E2-4EF6-90D6-8A15ACD6DE57
author	John C. Byrd Farrukh T Awan Nyla A Heerema Jeffrey A Jones Amy S Ruppert Gerard Lozanski Jennifer A Woyach Kami Maddocks Kerry Rogers Mollie Moran
title	wds:Q57169180-93AE3F87-6015-4926-8908-D7EA6E0FF6E7
title	Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia (en)
page(s)	wds:Q57169180-E879DCF0-936B-48B5-B187-DF9B2333275C
page(s)	1568-1572
instance of	wds:Q57169180-A61410AE-9967-41B1-A6A3-AE1CE7D68154
instance of	scholarly article
main subject	wds:Q57169180-1CE7BE47-938A-4608-A95A-225A299D05DA wds:Q57169180-4F4872E9-E20A-407D-A520-220BDD2A0445 wds:Q57169180-D7602174-453B-4FD1-8D29-4DBBA6A73128
main subject	chronic lymphocytic leukemia ibrutinib leukemia
PubMed ID	wds:Q57169180-82921C90-36B2-4E0E-84F8-E7133F6C5233
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30111609
PubMed ID	30111609
published in	wds:Q57169180-DE1DB72C-6FCE-4AD9-B3F3-11B886E41BF8
published in	Blood
issue	wds:Q57169180-85EFA0FB-131F-49DD-943B-EAAC3B2D7014
volume	wds:Q57169180-D8F3152F-F36B-47C4-AA70-DE82ABBB867B

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software